---
schema_version: "secwatch.filing_event.v1"
accession: "0001641172-25-012617"
form_type: "8-K"
ticker: "MAIA"
cik: "0001878313"
company_name: "MAIA Biotechnology, Inc."
filed_at: "2025-05-28T23:59:59+00:00"
generated_at: "2026-05-20T08:47:10.329721+00:00"
event_type: "other_material"
sentiment: "neutral"
materiality_score: 0.4
calibrated_materiality_score: 0.4
confidence: "high"
source: SEC EDGAR
---

# MAIA Biotechnology closes $695K private placement of stock and warrants for THIO-101 trial

## Summary
- Sold 463,332 shares and warrants at $1.50/share; warrants exercisable at $1.71, 5-year term, 6-month lockout.
- Director Stan Smith purchased 33,333 shares and warrants for ~$50,000.
- Gross proceeds ~$695,000; net proceeds to fund Step 1 of Part C of Phase II THIO-101 trial and working capital.
- Expected closing May 29, 2025; securities exempt from registration under Section 4(a)(2)/Rule 506.

## SEC filing metadata
- accession: 0001641172-25-012617
- form_type: 8-K
- ticker: MAIA
- cik: 0001878313
- company_name: MAIA Biotechnology, Inc.
- filed_at: 2025-05-28T23:59:59+00:00
- event_type: other_material
- sentiment: neutral
- materiality_score: 0.4
- calibrated_materiality_score: 0.4
- confidence: high
- sec_items: 1.01, 3.02, 8.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1878313/000164117225012617/0001641172-25-012617-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1878313/000164117225012617/form8-k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001641172-25-012617
- JSON: https://secwatch.observer/filing/0001641172-25-012617.json
- Plain text: https://secwatch.observer/filing/0001641172-25-012617.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.